BioNTech (NSDQ:BNTX) announced today that it acquired Kite’s solid tumor neoantigen T cell receptor (TCR) platform and its facility in Maryland. Mainz, Germany-based BioNTech said in a news release that the acquired clinical manufacturing facility in Gaithersburg, Md., will provide production capacity in support of U.S. clinical trials while complementing the company’s existing cell therapy…